Revolutionizing Heart Valve Replacement with Superior One-Year Results
Edwards Lifesciences’ SAPIEN 3 Ultra RESILIA valve has set a new standard in transcatheter aortic valve replacement (TAVR) outcomes, according to a study of over 9,000 patients presented at PCR London Valves 2024 and published in JACC: Cardiovascular Interventions.
Key Findings from the Study
- Outstanding Patient Outcomes:
- Extremely low mortality and reintervention rates.
- No paravalvular leak in 84.4% of cases.
- Larger effective orifice areas and lower gradients across all valve sizes.
- Rapid Recovery:
- Average hospital stay of just one day.
- 93% of patients discharged home.
- Significant quality-of-life improvement with a 31-point increase in KCCQ scores.
Innovating for Low-Risk Patients
Dr. Gilbert Tang emphasized the transformative impact for low-risk patients:
“This is the first large-scale study demonstrating improved survival and reduced paravalvular leaks with this latest generation valve. These advancements are game-changing for patients with longer life expectancies.”
Data-Driven Leadership in TAVR
Findings from the STS/ACC TVT Registry spotlight the innovation behind the RESILIA platform:
- Average patient age: 77 years with an STS risk score of 3.6.
- Improved valve durability, reducing complications compared to earlier generations.
Advancing Structural Heart Disease Treatment
With over a decade of clinical experience, Edwards continues to drive MedTech innovation, delivering solutions that improve survival, recovery, and quality of life for patients with structural heart disease.
Follow MEDWIRE.AI for updates on groundbreaking cardiovascular technologies and insights shaping the future of patient care.
